The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Ovid Therapeutics P/E ratio is -0.79. it has increased by a third in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Ovid Therapeutics’s P/E ratio

**Contents**hide

## What is Ovid Therapeutics P/E Ratio?

Ovid Therapeutics’ P/E ratio is -0.79, which represents a 81.19% increase over the same period last year. their average P / E ratio is -2.76 and their 5-year average is -2.89.

## What is Ovid Therapeutics Net EPS?

Ovid Therapeutics’ net earnings for the most recent quarter were -2.73$, which represents a 260.59% decrease over the same period last year.

## Who are Ovid Therapeutics Competitors?

Based on Jika.io AI model, Annovis Bio, Concert Pharmaceuticals, aTyr Pharma, Praxis Precision Medicines, Rhythm Pharmaceuticals, Sutro Biopharma, Trevi Therapeutics, Voyager Therapeutics are considered to be Ovid Therapeutics’s competitors because the companies operate within the same industry as Ovid Therapeutics and they are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Ovid Therapeutics.

## Who is Ovid Therapeutics’s Biggest competitor?

Ovid Therapeutics’ biggest competitor is Annovis Bio, based on the Jika.io AI model. it has a similar market capitalization to Ovid Therapeutics within the industry, it dominates a similar share of the market as Ovid Therapeutics, and it provides and markets very similar services.

## What industry is Ovid Therapeutics in?

Ovid Therapeutics is part of the biotechnology and healthcare industry.

## Ovid Therapeutics vs Annovis Bio

Market Cap: Ovid Therapeutics’s Market Cap of 152101360 is higher than Annovis Bio Market Cap of 108253584.

Average Volume: Ovid Therapeutics’s Average Volume of 184245.0 is lower than Annovis Bio Average Volume of 41500.0.

Beta: Ovid Therapeutics’s Beta of 1.58 is lower than Annovis Bio Beta of 2.12.

Revenue: Ovid Therapeutics’s Revenue of 208383.0 is higher than Annovis Bio Revenue of 0.0.

Net Income: Ovid Therapeutics’s Net Income of 122834.0 is higher than Annovis Bio Net Income of -14.487B.

Gross Profit: Ovid Therapeutics’s Gross Profit of 208383.0 is higher than Annovis Bio Gross Profit of 0.0.

Ebitda: Ovid Therapeutics’s Ebitda of 237.203M is higher than Annovis Bio Ebitda of -14.487B.

P/E Ratio: Ovid Therapeutics’s P/E Ratio of -0.79 is higher than Annovis Bio P/E Ratio of -0.01.

P/B Ratio: Ovid Therapeutics’s P/B Ratio of 0.92 is lower than Annovis Bio P/B Ratio of 2.57.

P/FCF Ratio: Ovid Therapeutics’s P/FCF Ratio of 2.24 is higher than Annovis Bio P/FCF Ratio of -11.18.

ROE: Ovid Therapeutics’s ROE of -1.03 is lower than Annovis Bio ROE of -319.21.

ROA: Ovid Therapeutics’s ROA of -1.0 is lower than Annovis Bio ROA of -334.86.

Return On Capital Employed: Ovid Therapeutics’s Return On Capital Employed of -0.38 is lower than Annovis Bio Return On Capital Employed of -0.41.

Assets (Total): Ovid Therapeutics’s Assets (Total) of 194.545M is lower than Annovis Bio Assets (Total) of 46.001M.

Debt (Total): Ovid Therapeutics’s Debt (Total) of 0.0 is lower than Annovis Bio Debt (Total) of 0.0.

Shareholders Equity: Ovid Therapeutics’s Shareholders Equity of 179.746M is lower than Annovis Bio Shareholders Equity of 44.495M.

## Ovid Therapeutics vs Concert Pharmaceuticals

Market Cap: Ovid Therapeutics’s Market Cap of 152101360 is lower than Concert Pharmaceuticals Market Cap of 205788112.

Average Volume: Ovid Therapeutics’s Average Volume of 184245.0 is lower than Concert Pharmaceuticals Average Volume of 831701.0.

Beta: Ovid Therapeutics’s Beta of 1.58 is higher than Concert Pharmaceuticals Beta of 0.31.

Revenue: Ovid Therapeutics’s Revenue of 208383.0 is lower than Concert Pharmaceuticals Revenue of 32578.0.

Net Income: Ovid Therapeutics’s Net Income of 122834.0 is higher than Concert Pharmaceuticals Net Income of -80051.0.

Gross Profit: Ovid Therapeutics’s Gross Profit of 208383.0 is higher than Concert Pharmaceuticals Gross Profit of 0.0.

Ebitda: Ovid Therapeutics’s Ebitda of 237.203M is higher than Concert Pharmaceuticals Ebitda of 1.399M.

P/E Ratio: Ovid Therapeutics’s P/E Ratio of -0.79 is lower than Concert Pharmaceuticals P/E Ratio of -4.47.

P/S Ratio: Ovid Therapeutics’s P/S Ratio of -0.74 is lower than Concert Pharmaceuticals P/S Ratio of 4.99.

P/B Ratio: Ovid Therapeutics’s P/B Ratio of 0.92 is lower than Concert Pharmaceuticals P/B Ratio of 2.12.

P/FCF Ratio: Ovid Therapeutics’s P/FCF Ratio of 2.24 is higher than Concert Pharmaceuticals P/FCF Ratio of -2.43.

ROE: Ovid Therapeutics’s ROE of -1.03 is higher than Concert Pharmaceuticals ROE of -0.35.

ROA: Ovid Therapeutics’s ROA of -1.0 is higher than Concert Pharmaceuticals ROA of -0.28.

Return On Capital Employed: Ovid Therapeutics’s Return On Capital Employed of -0.38 is lower than Concert Pharmaceuticals Return On Capital Employed of -0.78.

Gross Profit Margin: Ovid Therapeutics’s Gross Profit Margin of -1.01 is lower than Concert Pharmaceuticals Gross Profit Margin of 0.0.

Assets (Total): Ovid Therapeutics’s Assets (Total) of 194.545M is higher than Concert Pharmaceuticals Assets (Total) of 165.316M.

Debt (Total): Ovid Therapeutics’s Debt (Total) of 0.0 is lower than Concert Pharmaceuticals Debt (Total) of 1.155M.

## Ovid Therapeutics vs aTyr Pharma

Market Cap: Ovid Therapeutics’s Market Cap of 152101360 is higher than aTyr Pharma Market Cap of 81082424.

Average Volume: Ovid Therapeutics’s Average Volume of 184245.0 is lower than aTyr Pharma Average Volume of 95155.0.

Beta: Ovid Therapeutics’s Beta of 1.58 is higher than aTyr Pharma Beta of 1.57.

Revenue: Ovid Therapeutics’s Revenue of 208383.0 is higher than aTyr Pharma Revenue of 10751.0.

Net Income: Ovid Therapeutics’s Net Income of 122834.0 is higher than aTyr Pharma Net Income of 0.0.

Gross Profit: Ovid Therapeutics’s Gross Profit of 208383.0 is higher than aTyr Pharma Gross Profit of 0.0.

Ebitda: Ovid Therapeutics’s Ebitda of 237.203M is higher than aTyr Pharma Ebitda of -34015.0.

P/E Ratio: Ovid Therapeutics’s P/E Ratio of -0.79 is lower than aTyr Pharma P/E Ratio of -2.66.

P/S Ratio: Ovid Therapeutics’s P/S Ratio of -0.74 is lower than aTyr Pharma P/S Ratio of 7.478M.

P/B Ratio: Ovid Therapeutics’s P/B Ratio of 0.92 is higher than aTyr Pharma P/B Ratio of 0.82.

P/FCF Ratio: Ovid Therapeutics’s P/FCF Ratio of 2.24 is higher than aTyr Pharma P/FCF Ratio of -2.73.

ROE: Ovid Therapeutics’s ROE of -1.03 is higher than aTyr Pharma ROE of -0.33.

ROA: Ovid Therapeutics’s ROA of -1.0 is higher than aTyr Pharma ROA of -0.29.

Return On Capital Employed: Ovid Therapeutics’s Return On Capital Employed of -0.38 is lower than aTyr Pharma Return On Capital Employed of -0.4.

Gross Profit Margin: Ovid Therapeutics’s Gross Profit Margin of -1.01 is lower than aTyr Pharma Gross Profit Margin of 0.0.

Assets (Total): Ovid Therapeutics’s Assets (Total) of 194.545M is higher than aTyr Pharma Assets (Total) of 115.537M.

Debt (Total): Ovid Therapeutics’s Debt (Total) of 0.0 is lower than aTyr Pharma Debt (Total) of 1.378M.

## Ovid Therapeutics vs Praxis Precision Medicines

Market Cap: Ovid Therapeutics’s Market Cap of 152101360 is higher than Praxis Precision Medicines Market Cap of 94664544.

Average Volume: Ovid Therapeutics’s Average Volume of 184245.0 is higher than Praxis Precision Medicines Average Volume of 1.402M.

Beta: Ovid Therapeutics’s Beta of 1.58 is higher than Praxis Precision Medicines Beta of 0.0.

Revenue: Ovid Therapeutics’s Revenue of 208383.0 is higher than Praxis Precision Medicines Revenue of 0.0.

Net Income: Ovid Therapeutics’s Net Income of 122834.0 is higher than Praxis Precision Medicines Net Income of -167.061M.

Gross Profit: Ovid Therapeutics’s Gross Profit of 208383.0 is higher than Praxis Precision Medicines Gross Profit of 0.0.

Ebitda: Ovid Therapeutics’s Ebitda of 237.203M is higher than Praxis Precision Medicines Ebitda of -167.15M.

P/E Ratio: Ovid Therapeutics’s P/E Ratio of -0.79 is higher than Praxis Precision Medicines P/E Ratio of -0.3.

P/B Ratio: Ovid Therapeutics’s P/B Ratio of 0.92 is higher than Praxis Precision Medicines P/B Ratio of 0.49.

P/FCF Ratio: Ovid Therapeutics’s P/FCF Ratio of 2.24 is higher than Praxis Precision Medicines P/FCF Ratio of -0.61.

ROE: Ovid Therapeutics’s ROE of -1.03 is lower than Praxis Precision Medicines ROE of -1.18.

ROA: Ovid Therapeutics’s ROA of -1.0 is lower than Praxis Precision Medicines ROA of -1.32.

Return On Capital Employed: Ovid Therapeutics’s Return On Capital Employed of -0.38 is lower than Praxis Precision Medicines Return On Capital Employed of -1.07.

Assets (Total): Ovid Therapeutics’s Assets (Total) of 194.545M is lower than Praxis Precision Medicines Assets (Total) of 292.747M.

Debt (Total): Ovid Therapeutics’s Debt (Total) of 0.0 is lower than Praxis Precision Medicines Debt (Total) of 8.622M.

Shareholders Equity: Ovid Therapeutics’s Shareholders Equity of 179.746M is lower than Praxis Precision Medicines Shareholders Equity of 250.812M.

## About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, develops effective medicines for patients and families with neurological disorders in the United States. the company is developing OV101, a drug candidate in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for the treatment of epilepsies. it also develops OV882, a short-lived RNA gene therapy for the treatment of angelman syndrome, and OV815 for the treatment of kinesin-associated neurological disorders. the company has agreements with Healx, AstraZeneca AB, H. Lundbeck A/S and Northwestern University, as well as Marinus Pharmaceuticals, Inc., which was founded in 2014 and has its headquarters in New York, New York.